Substance P Mediates Proinflammatory Cytokine Release From Mesenteric Adipocytes in Inflammatory Bowel Disease Patients

Cellular and Molecular Gastroenterology and Hepatology

Volumn 1, Issue 4, 2015, Pages 420-432

  Sideri, Aristea ^a,b   Bakirtzi, Kyriaki ^a   Shih, David Q ^c   Koon, Hon Wai ^a   Fleshner, Phillip ^c   Arsenescu, Razvan ^d   Arsenescu, Violeta ^d   Turner, Jerrold R ^e   Karagiannides, Iordanes ^a   Pothoulakis, Charalabos ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CRETE   (Greece)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cytokines; Interleukin 17; Preadipocytes; Substance P

Indexed keywords

CXCL9 CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 4; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROKININ 1 RECEPTOR; NEUROKININ 2 RECEPTOR; NEUROKININ 3 RECEPTOR; PLATELET DERIVED GROWTH FACTOR A; SUBSTANCE P; VASCULOTROPIN A;

ADIPOCYTE; ARTICLE; COLON BIOPSY; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATORY BOWEL DISEASE; MALE; MEDIATOR RELEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN EXPRESSION; ULCERATIVE COLITIS;

EID: 84937706647     PISSN: None     EISSN: 2352345X     Source Type: Journal    
DOI: 10.1016/j.jcmgh.2015.03.003     Document Type: Article

References (64)

1. Chang M.M., Leeman S.E. Isolation of a sialogogic peptide from bovine hypothalamic tissue and its characterization as substance P. J Biol Chem 1970, 245:4784-4790.
2. Steinhoff M.S., von Mentzer B., Geppetti P., et al. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol Rev 2014, 94:265-301.
3. Koon H.W., Pothoulakis C. Immunomodulatory properties of substance P. Ann NY Acad Sci 2006, 1088:23-40.
4. Koon H.W., Pothoulakis C. Immunomodulatory properties of substance P: the gastrointestinal system as a model. Ann NY Acad Sci 2006, 1088:23-40.
5. Kaser A., Zeissig S., Blumberg R.S. Inflammatory bowel disease. Annu Rev Immunol 2010, 28:573-621.
6. Gross K.J., Pothoulakis C. Role of neuropeptides in inflammatory bowel disease. Inflamm Bowel Dis 2007, 13:918-932.
7. Mantyh C.R., Vigna S.R., Bollinger R.R., et al. Differential expression of substance P receptors in patients with Crohn's disease and ulcerative colitis. Gastroenterology 1995, 109:850-860.
8. Ottaway C.A. Role of the neuroendocrine system in cytokine pathways in inflammatory bowel disease. Aliment Pharmacol Ther 1996, 10(Suppl 2):10-15.
9. Pothoulakis C., Castagliuolo I., Leeman S.E., et al. Substance P receptor expression in intestinal epithelium in clostridium difficile toxin A enteritis in rats. Am J Physiol 1998, 275:G68-G75.
10. Renzi D., Pellegrini B., Tonelli F., et al. Substance P (neurokinin-1) and neurokinin A (neurokinin-2) receptor gene and protein expression in the healthy and inflamed human intestine. Am J Pathol 2000, 157:1511-1522.
11. Mantyh C.R., Vigna S.R., Maggio J.E., et al. Substance P binding sites on intestinal lymphoid aggregates and blood vessels in inflammatory bowel disease correspond to authentic NK-1 receptors. Neurosci Lett 1994, 178:255-259.
12. Castagliuolo I., Riegler M., Pasha A., et al. Neurokinin-1 (NK-1) receptor is required in Clostridium difficile-induced enteritis. J Clin Invest 1998, 101:1547-1550.
13. Castagliuolo I., Morteau O., Keates A.C., et al. Protective effects of neurokinin-1 receptor during colitis in mice: role of the epidermal growth factor receptor. Br J Pharmacol 2002, 136:271-279.
14. Koon H.W., Zhao D., Zhan Y., et al. Substance P mediates antiapoptotic responses in human colonocytes by Akt activation. Proc Natl Acad Sci USA 2007, 104:2013-2018.
15. Pothoulakis C., Castagliuolo I., LaMont J.T., et al. CP-96,345, a substance P antagonist, inhibits rat intestinal responses to Clostridium difficile toxin A but not cholera toxin. Proc Natl Acad Sci USA 1994, 91:947-951.
16. Stucchi A.F., Shofer S., Leeman S., et al. NK-1 antagonist reduces colonic inflammation and oxidative stress in dextran sulfate-induced colitis in rats. Am J Physiol Gastrointest Liver Physiol 2000, 279:G1298-G1306.
17. Weinstock J.V., Blum A., Metwali A., et al. Substance P regulates Th1-type colitis in IL-10 knockout mice. J Immunol 2003, 171:3762-3767.
18. Di Sebastiano P., Grossi L., Di Mola F.F., et al. SR140333, a substance P receptor antagonist, influences morphological and motor changes in rat experimental colitis. Dig Dis Sci 1999, 44:439-444.
19. Koon H.W., Zhao D., Na X., et al. Metalloproteinases and transforming growth factor-alpha mediate substance P-induced mitogen-activated protein kinase activation and proliferation in human colonocytes. J Biol Chem 2004, 279:45519-45527.
20. Castagliuolo I., Valenick L., Liu J., Pothoulakis C. Epidermal growth factor receptor transactivation mediates substance P-induced mitogenic responses in U-373 MG cells. J Biol Chem 2000, 275:26545-26550.
21. Goode T., O'Connell J., Anton P., et al. Neurokinin-1 receptor expression in inflammatory bowel disease: molecular quantitation and localisation. Gut 2000, 47:387-396.
22. Castagliuolo I., Keates A.C., Qiu B., et al. Increased substance P responses in dorsal root ganglia and intestinal macrophages during Clostridium difficile toxin A enteritis in rats. Proc Natl Acad Sci USA 1997, 94:4788-4793.
23. Lieb K., Fiebich B.L., Berger M., et al. The neuropeptide substance P activates transcription factor NF-kappa B and kappa B-dependent gene expression in human astrocytoma cells. J Immunol 1997, 159:4952-4958.
24. Zhao D., Kuhnt-Moore S., Zeng H., et al. Substance P-stimulated interleukin-8 expression in human colonic epithelial cells involves Rho family small GTPases. Biochem J 2002, 368:665-672.
25. Blain A., Cattan S., Beaugerie L., et al. Crohn's disease clinical course and severity in obese patients. Clin Nutr 2002, 21:51-57.
26. Desreumaux P., Ernst O., Geboes K., et al. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology 1999, 117:73-81.
27. Herlinger H., Furth E.E., Rubesin S.E. Fibrofatty proliferation of the mesentery in Crohn disease. Abdom Imaging 1998, 23:446-448.
28. Karmiris K., Koutroubakis I.E., Xidakis C., et al. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis 2006, 12:100-105.
29. Tchkonia T., Thomou T., Zhu Y., et al. Mechanisms and metabolic implications of regional differences among fat depots. Cell Metab 2013, 17:644-656.
30. Karagiannides I., Kokkotou E., Tansky M., et al. Induction of colitis causes inflammatory responses in fat depots: evidence for substance P pathways in human mesenteric preadipocytes. Proc Natl Acad Sci USA 2006, 103:5207-5212.
31. Gross K., Karagiannides I., Thomou T., et al. Substance P promotes expansion of human mesenteric preadipocytes through proliferative and antiapoptotic pathways. Am J Physiol Gastrointest Liver Physiol 2009, 296:G1012-G1019.
32. Karagiannides I., Bakirtzi K., Kokkotou E., et al. Role of substance P in the regulation of glucose metabolism via insulin signaling-associated pathways. Endocrinology 2011, 152:4571-4580.
33. Karagiannides I., Stavrakis D., Bakirtzi K., et al. Substance P (SP)-neurokinin-1 receptor (NK-1R) alters adipose tissue responses to high-fat diet and insulin action. Endocrinology 2011, 152:2197-2205.
34. Tchkonia T., Giorgadze N., Pirtskhalava T., et al. Fat depot origin affects adipogenesis in primary cultured and cloned human preadipocytes. Am J Physiol Regul Integr Comp Physiol 2002, 282:R1286-R1296.
35. Bernstein C.N., Robert M.E., Eysselein V.E. Rectal substance P concentrations are increased in ulcerative colitis but not in Crohn's disease. Am J Gastroenterol 1993, 88:908-913.
36. Mazumdar S., Das K.M. Immunocytochemical localization of vasoactive intestinal peptide and substance P in the colon from normal subjects and patients with inflammatory bowel disease. Am J Gastroenterol 1992, 87:176-181.
37. Simeonidis S., Castagliuolo I., Pan A., et al. Regulation of the NK-1 receptor gene expression in human macrophage cells via an NF-kappa B site on its promoter. Proc Natl Acad Sci USA 2003, 100:2957-2962.
38. + Th17 cells. J Exp Med 2012, 209:1595-1609.
39. Liu Z.J., Geboes K., Colpaert S., et al. IL-15 is highly expressed in inflammatory bowel disease and regulates local T cell-dependent cytokine production. J Immunol 2000, 164:3608-3615.
40. Schwartz D. Anti-IL-12/23: the next big thing in IBD?. Inflamm Bowel Dis 2009, 15:1927-1928.
41. Reenaers C., Louis E., Belaiche J. Current directions of biologic therapies in inflammatory bowel disease. Therap Adv Gastroenterol 2010, 3:99-106.
42. Daig R., Andus T., Aschenbrenner E., et al. Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease. Gut 1996, 38:216-222.
43. Parkes M., Satsangi J., Jewell D. Contribution of the IL-2 and IL-10 genes to inflammatory bowel disease (IBD) susceptibility. Clin Exp Immunol 1998, 113:28-32.
44. Yarkoni S., Sagiv Y., Kaminitz A., Askenasy N. Interleukin 2 targeted therapy in inflammatory bowel disease. Gut 2009, 58:1705-1706.
45. Kadivar K., Ruchelli E.D., Markowitz J.E., et al. Intestinal interleukin-13 in pediatric inflammatory bowel disease patients. Inflamm Bowel Dis 2004, 10:593-598.
46. Kucharzik T., Lugering N., Weigelt H., et al. Immunoregulatory properties of IL-13 in patients with inflammatory bowel disease; comparison with IL-4 and IL-10. Clin Exp Immunol 1996, 104:483-490.
47. Scaldaferri F., Vetrano S., Sans M., et al. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 2009, 136:585-595 e585.
48. Peyrin-Biroulet L. Anti-TNF therapy in inflammatory bowel diseases: a huge review. Minerva Gastroenterol Dietol 2010, 56:233-243.
49. Rehman M.Q., Beal D., Liang Y., et al. B cells secrete eotaxin-1 in human inflammatory bowel disease. Inflamm Bowel Dis 2013, 19:922-933.
50. Kanazawa S., Tsunoda T., Onuma E., et al. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol 2001, 96:822-828.
51. Lacher M., Kappler R., Berkholz S., et al. Association of a CXCL9 polymorphism with pediatric Crohn's disease. Biochem Biophys Res Commun 2007, 363:701-707.
52. -/- mice. J Immunol 2003, 171:1401-1406.
53. Banks C., Bateman A., Payne R., et al. Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J Pathol 2003, 199:28-35.
54. Ansari N., Abdulla J., Zayyani N., et al. Comparison of RANTES expression in Crohn's disease and ulcerative colitis: an aid in the differential diagnosis?. J Clin Pathol 2006, 59:1066-1072.
55. Dabritz J., Bonkowski E., Chalk C., et al. Granulocyte macrophage colony-stimulating factor auto-antibodies and disease relapse in inflammatory bowel disease. Am J Gastroenterol 2013, 108:1901-1910.
56. Gathungu G., Kim M.O., Ferguson J.P., et al. Granulocyte-macrophage colony-stimulating factor autoantibodies: a marker of aggressive Crohn's disease. Inflamm Bowel Dis 2013, 19:1671-1680.
57. Agyekum S., Church A., Sohail M., et al. Expression of lymphotoxin-beta (LT-beta) in chronic inflammatory conditions. J Pathol 2003, 199:115-121.
58. Lacey D.C., Achuthan A., Fleetwood A.J., et al. Defining GM-CSF- and macrophage-CSF-dependent macrophage responses by in vitro models. J Immunol 2012, 188:5752-5765.
59. Arneja A., Johnson H., Gabrovsek L., et al. Qualitatively different T cell phenotypic responses to IL-2 versus IL-15 are unified by identical dependences on receptor signal strength and duration. J Immunol 2014, 192:123-135.
60. Malek T.R., Yu A.X., Scibelli P., et al. Broad programming by IL-2 receptor signaling for extended growth to multiple cytokines and functional maturation of antigen-activated T cells. J Immunol 2001, 166:1675-1683.
61. Ni G.Y., Wang Y.J., Wu X.L., et al. Graphene oxide absorbed anti-IL10R antibodies enhance LPS induced immune responses in vitro and in vivo. Immunol Lett 2012, 148:126-132.
62. Ishigame H., Kakuta S., Nagai T., et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 2009, 30:108-119.
63. Beinborn M., Blum A., Hang L., et al. TGF-beta regulates T-cell neurokinin-1 receptor internalization and function. Proc Natl Acad Sci USA 2010, 107:4293-4298.
64. Rovedatti L., Kudo T., Biancheri P., et al. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut 2009, 58:1629-1636.